English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Viability of autoantibody-targets: How to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis

Mayer, M. C., Hohlfeld, R., & Meinl, E. (2012). Viability of autoantibody-targets: How to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis. JOURNAL OF THE NEUROLOGICAL SCIENCES, 319(1-2), 2-7. doi:10.1016/j.jns.2012.05.018.

Item is

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Mayer, Marie Cathrin1, Author           
Hohlfeld, Reinhard1, Author           
Meinl, Edgar1, Author           
Affiliations:
1Department: Neuroimmunology / Wekerle, MPI of Neurobiology, Max Planck Society, ou_1113547              

Content

show
hide
Free keywords: MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; ACUTE DISSEMINATED ENCEPHALOMYELITIS; B-CELL AUTOIMMUNITY; TERM-FOLLOW-UP; ANTIMYELIN ANTIBODIES; NEUROMYELITIS-OPTICA; MYELIN/OLIGODENDROCYTE GLYCOPROTEIN; DEMYELINATING DISEASES; PEDIATRIC-PATIENTS; BASIC-PROTEINMultiple sclerosis; Acute disseminated encephalomyelitis; Biomarkers; Autoantigens; Myelin oligodendrocyte glycoprotein; Autoantibody detection methods;
 Abstract: The growing complexity number of multiple sclerosis (MS) therapy emphasizes the need for an individualized approach, tailoring therapy to the needs of the individual patient. There is evidence supporting the immunopathological heterogeneity of MS, based on the analysis of biopsy and autopsy tissues. In clinical practice it is impossible to differentiate between the pathological subtypes of MS, because blood or CSF markers of pathological heterogeneity are lacking. Identification of such markers would be important, because "tailored therapy" and "biomarkers for patient stratification" may be considered as two sides of the same coin. In this article, we discuss the emerging role of autoantibodies as potential biomarkers, focusing on myelin oligodendrocyte glycoprotein (MUG) as one of the best characterized autoantigens in MS. In addition, we discuss several strategies for the identification of novel candidate autoantigens. (C) 2012 Elsevier B.V. All rights reserved.

Details

show
hide
Language(s): eng - English
 Dates: 2012-08-15
 Publication Status: Published in print
 Pages: 6
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Identifiers: ISI: 000306246900002
DOI: 10.1016/j.jns.2012.05.018
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: JOURNAL OF THE NEUROLOGICAL SCIENCES
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS : ELSEVIER SCIENCE BV
Pages: - Volume / Issue: 319 (1-2) Sequence Number: - Start / End Page: 2 - 7 Identifier: ISSN: 0022-510X